Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
H018 ointment
- Development stage
- Phase 2
- Lead developer
- Institute of Dermatology, Chinese Academy of Medical Sciences
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
H018 ointment is an investigational topical small molecule Janus kinase (JAK) inhibitor being developed by the Institute of Dermatology, Chinese Academy of Medical Sciences. It is primarily targeted for the treatment of vitiligo, an autoimmune skin condition characterized by the loss of pigment-producing melanocytes. By inhibiting the JAK signaling pathway, H018 aims to suppress the immune-mediated destruction of melanocytes and promote repigmentation. The drug is currently in Phase I clinical development, with studies evaluating its safety, tolerability, and pharmacokinetics in healthy volunteers.
02
Targets
Beyond the preview
Go deeper on H018 ointment.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on H018 ointment.